Stock NGEN NERVGEN PHARMA CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.09 CAD +1.46% Intraday chart for NervGen Pharma Corp. +3.47% -22.59%
Apr. 17 NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update MT
Apr. 17 NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update
MT
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
NE
NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
AQ
NervGen Pharma Closes C$23 Million Bought Deal Financing
MT
NervGen Completes $23 Million Bought Deal Financing
NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN
AQ
NervGen Pharma Raising C$20.1 Million in Bought-Deal Offering of Share Units
MT
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING
AQ
Canadian Investment Regulatory Organization Trading Halt - NGEN
AQ
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
NE
NervGen Pharma Grants Stock Options
NE
NervGen Pharma Corp. Plans to Initiate A New Study in Which Subjects Completes Open-Label Nvg-291
CI
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
NE
NervGen Pharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
NE
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki
NE
NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
CI
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury
NE
Nervgen Pharma Appoints John Ruffolo to Board of Directors
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGEN Stock
  4. News NervGen Pharma Corp.